Shilpa Medicare shares up 2% after arm partners with Swiss-based mAbTree Biologics for cancer drug
The therapy, a fully human monoclonal antibody, targets a newly identified immune checkpoint protein that could enhance ...
The Manila Times1d
Anti-HER2 Biparatopic ADC JSKN003 Has Been Granted Breakthrough-Therapy Designation for the Treatment of PROC
Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results
Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 millionTransaction expected to close by ...
Personalized cancer vaccine proves promising in a phase 1 trial
Researchers at the Icahn School of Medicine at Mount Sinai, led by Nina Bhardwaj, MD, Ph.D., Ward-Coleman Chair in Cancer ...
Could This Antibody Be The Future of Cancer Treatment? Researchers Say Yes!
Scientists at King’s College London have developed an innovative IgE antibody therapy that activates the immune system to ...
Synthetic mRNA therapy: Study introduces weapon against metastatic cancer without harmful side effects
Cancer metastasis, the spread of cancer to organs, is a major cause of cancer-related deaths. Once cancer spreads to multiple ...
Shilpa Medicare’s arm partners with Swiss-based mAbTree Biologics for novel cancer therapy
The therapy, a fully human monoclonal antibody, targets a newly identified immune checkpoint protein that could enhance ...
Game-changer in cancer treatment: New antibody therapy could replace chemotherapy to fight tumours
Immunotherapy, or antibody treatment that activates the patient's own immune system against cancer, is increasingly being ...
AstraZeneca boosts cancer therapies push with $1 billion EsoBiotec buy
Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, ...
AbbVie reports final analysis from Phase III trial of Elahere for ovarian cancer
US-based pharmaceutical company AbbVie has reported the final analysis from the Phase III MIRASOL trial, which assessed its ...
The Manila Times1d
Akeso's Penpulimab Receives NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer
Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for ...